Publications en collaboration avec des chercheurs de The Bristol-Myers Squibb Children's Hospital (27)

2024

  1. Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 84

2023

  1. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 2007-2019

  2. Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

    Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212

  3. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

    ESMO Open, Vol. 8, Núm. 6

2022

  1. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308

  2. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 2, pp. 161-170

2021

  1. Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273))

    ESMO Open

  2. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 198-211

  3. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

    ESMO Open, Vol. 6, Núm. 5

  4. The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

    Leukemia and Lymphoma

2019

  1. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation

    New England Journal of Medicine, Vol. 380, Núm. 16, pp. 1509-1524

  2. Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary

    European Heart Journal: Acute Cardiovascular Care, Vol. 8, Núm. 8, pp. 745-754

2018

  1. Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))

    European Urology

  2. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

    New England Journal of Medicine, Vol. 378, Núm. 14, pp. 1277-1290

  3. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden

    New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2093-2104

  4. Telotristat ethyl in carcinoid syndrome: Safety and efficacy in the TELECAST phase 3 trial

    Endocrine-Related Cancer, Vol. 25, Núm. 3, pp. 309-322

2017

  1. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]

    European Urology, Vol. 72, Núm. 6, pp. 962-971

  2. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

    Hepatology International, Vol. 11, Núm. 2, pp. 188-198

  3. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer

    New England Journal of Medicine, Vol. 376, Núm. 25, pp. 2415-2426

  4. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057)

    Journal of Clinical Oncology, Vol. 35, Núm. 35, pp. 3924-3933